[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cidp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cidp":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,64,91,114,134,150,177,208,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100599987","phase-3-a-study-to-assess-the-efficacy-and-safety-of-empasiprubart-in-adults-with-cidp-100599987",false,"NCT07091630","A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP","A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy","emnergize","Inclusion Criteria:\n\n* Meets criteria for CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP\n* Has residual disability and active disease\n* Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)\n* Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP\n\nExclusion Criteria:\n\n* Meets the criteria for possible CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Sensory CIDP (including sensory-predominant CIDP)\n* Polyneuropathy of other causes\n* Clinical diagnosis of systemic lupus erythematosus (SLE)\n* Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Femnergize",[27,28,29],"Chronic Inflammatory Demyelinating Polyneuropathy","CIDP","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":34},"2025-09-16",{"date":38,"type":21},"2031-01-23",{"name":40,"class":41},"argenx","INDUSTRY",61,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100586793","phase-3-a-study-to-assess-efficacy-and-safety-of-empasiprubart-versus-ivig-in-adults-with-cidp-100586793","NCT06920004","A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP","A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy","emvigorate","Inclusion Criteria:\n\n* Meets criteria for CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP\n* Has responded to IVIg in the past 5 years\n* Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g\u002Fkg\n* Has residual disability and active disease\n\nExclusion Criteria:\n\n* Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes\n* Meets the criteria for possible or sensory CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021)\n* Use of other long-acting immunomodulatory treatment",{"count":52,"type":21},218,[24],"The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Femvigorate",[27,28,56],"CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",{"date":33,"type":34},{"date":59,"type":34},"2025-08-22",{"date":61,"type":21},"2030-09",{"name":40,"class":41},75,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100643609","phase-2-a-study-to-assess-the-correct-dose-safety-and-efficacy-of-empasiprubart-in-adolescent-participants-aged-12-to-less-than-18-years-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-100643609","NCT07638566","A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","emlight","Inclusion Criteria:\n\n* Is aged 12 to \\\u003C18 years.\n* Meets criteria for CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021).\n* Has a diagnosis of either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP.\n\nExclusion Criteria:\n\n* Possible CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021).\n* Sensory CIDP (including sensory-predominant CIDP).\n* Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP, or that puts the participant at undue risk.\n* Prior use of other long-acting immunomodulatory treatment.","12 Years","17 Years",{"count":75,"type":21},6,[77,24],"PHASE2","The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP.\n\nThe study consists of an open label treatment phase where participants will receive empasiprubart for up to 27 months approximately. After the final dose of empasiprubart, participants will enter a safety follow-up period for up to 14 months approximately.\n\nThe overall study duration for each participant is up to 43 months.\n\nMore information can be found here: clinicaltrials.argenx.com\u002Femlight",[29,80,28,81],"CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)","Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","NOT_YET_RECRUITING","2026-06-05",{"date":85,"type":34},"2026-06-10",{"date":87,"type":21},"2026-09",{"date":89,"type":21},"2031-08",{"name":40,"class":41},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100430177","phase-2-immunoadsorption-versus-immunoglobulins-for-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100430177","NCT04881682","Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IVITOC","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines\n* Disease duration of 3 years or less\n* Age 18 years or above\n* Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician\n\nExclusion Criteria:\n\n* Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg\u002Fl, or evidence of nitrite-positive urinary tract infection\n* Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment\n* immunoglobulin A deficiency\n* Other contraindications against immunoadsorption or intravenous immunoglobulins",{"count":99,"type":21},20,[77],"This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).",[28],"2026-04-30",{"date":105,"type":34},"2026-05-01",{"date":107,"type":34},"2023-05-01",{"date":109,"type":21},"2028-03-01",{"name":111,"class":112},"University of Ulm","OTHER",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100613272","real-world-efgartigimod-effectiveness-in-cidp-a-prospective-study-100613272","NCT07264426","Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study","Inclusion Criteria:\n\n* Aged ≥18 years at time of providing informed consent\n* Diagnosed with CIDP\n* Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country\n* Efgartigimod treatment-naïve at time of screening\n\nExclusion Criteria:\n\n* Polyradiculoneuropathy due to any other cause(s)\n* Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod",{"count":121,"type":21},200,"OBSERVATIONAL","The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the \"treatment journey\" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.\n\nAs this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.\n\nEach participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.",[29,28,80],"2026-04-22",{"date":127,"type":34},"2026-04-23",{"date":129,"type":34},"2025-08-11",{"date":131,"type":21},"2029-10",{"name":40,"class":41},23,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":149,"locationsCount":4},"100422200","pre-approval-access-for-efgartigimod-ph20-sc-in-adults-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100422200","NCT04777734","Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Pre-Approval Access for Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Inclusion Criteria:\n\n* Cannot be included in an ongoing clinical study and cannot be satisfactorily treated with a product that has regulatory approval\n* Is ≥18 years of age at the time of signing the informed consent form\n* Patient has a diagnosis of CIDP according to the 2021 EAN\u002FPNS CIDP guidelines\n* Patient has progressive or relapsing active disease after prior treatment with corticosteroids or immunoglobulins\n\nExclusion Criteria:\n\n* Known autoimmune disease or any medical condition that, in the opinion of the treating physician, would interfere with an accurate assessment of clinical symptoms of CIDP or that puts the patient at undue risk\n* Is currently being treated or plans to start treatment with monoclonal antibodies or treatments that contain the human Fc domain of the IgG subclass\n* Pregnant or lactating state or intention to become pregnant during the program","EXPANDED_ACCESS","The aim of the Pre-Approval Access program is to provide efgartigimod PH20 SC treatment to patients with CIDP who are ineligible to participate in a clinical study and have unmet medical need despite available treatment options. The program will continue until the patient discontinues treatment or until the reimbursement process for CIDP concludes, whichever comes first.",[144,28],"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","AVAILABLE","2026-03-20",{"date":148,"type":34},"2026-03-24",{"name":40,"class":41},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":113},"100484176","phase-1-ivig-vs-scig-in-cidp-100484176","NCT05584631","IVIG vs SCIG in CIDP","The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration","Inclusion Criteria:\n\n* Patients aged \\>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences \u002F Peripheral Nerve Society CIDP diagnostic criteria).\n* 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg\u002Fkg dose for SCIG.\n\nExclusion Criteria:\n\n* Patients receiving IVIG for indications other than CIDP will be excluded.\n* Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \\\u003C 50 mL\u002Fmin) will be excluded\n* Active malignancies\n* Diabetes\n* Myasthenia gravis\n* Immunodeficiency\n* Autoimmune disease","65 Years",{"count":99,"type":21},[160],"PHASE1","Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.",[28,163,27],"Immunoglobulin Deficiency",[165,166,167],"immunoglobulin","pharmacokinetics","obesity","2025-12-10",{"date":170,"type":34},"2025-12-11",{"date":172,"type":34},"2022-09-11",{"date":174,"type":21},"2026-12-01",{"name":176,"class":112},"Rutgers, The State University of New Jersey",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":187,"studyType":122,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100593450","vitaccess-real-cidp-registry-100593450","NCT07006597","Vitaccess Real CIDP Registry","Vitaccess Real CIDP Registry: A Prospective International Observational Patient Registry in Chronic Inflammatory Demyelinating Polyneuropathy Linking Clinical and Patient-Reported Data","VRCIDP","Inclusion Criteria:\n\n* Adult (age ≥18 years) with a clinically confirmed diagnosis of CIDP by their treating neurologist\n* Resident in the US, UK or Germany\n* Access to a smartphone\u002Ftablet\u002Fcomputer\u002Flaptop\n* Willing and able to provide informed consent in their local language to take part in the study\n\nExclusion Criteria:\n\nNone",{"count":186,"type":21},300,"10 Years","Vitaccess Real CIDP (VRCIDP) is a patient registry designed to capture longitudinal observational data on chronic inflammatory demyelinating polyneuropathy (CIDP), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 300 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from electronic medical records (EMR). Patient reported and eCRF data will be linked via a unique ID and PIN assigned to each participant at enrolment.\n\nPatients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.",[27,28],[191,192,193,194,195,196,197,198],"patient registry","longitudinal observational data","patient-reported outcomes","Nervous System Disease","Autoimmune Disease","Neurodegenerative Disease","Immune System Disease","Nervous System Diseases","2025-06-04",{"date":201,"type":34},"2025-06-05",{"date":203,"type":21},"2025-07-31",{"date":205,"type":21},"2035-07",{"name":207,"class":41},"Vitaccess Ltd",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":215,"enrollmentInfo":216,"targetDuration":217,"studyType":122,"phases":4,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":113},"100439607","biorepository-and-registry-for-plasma-exchange-patients-100439607","NCT05004493","Biorepository and Registry for Plasma Exchange Patients","Assessment of Changes in Normal and Pathological Immune Factors in Patients Undergoing Plasma Exchange","Pts undergoing plasma exchange therapy are eligible to be in this protocol","99 Years",{"count":121,"type":21},"1 Year","Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies. At our facility about 400 of these procedures are performed annually on 40-60 different patients. These procedures are considered within the standard of care for these patients and are covered by insurance. This study will not influence the treatment plan for subjects who participate in this study. The goal of the study is to collect and cryopreserve blood biospecimens (plasma, serum, PBMCs) for current and future studies. Any patient undergoing plasma exchange procedures will be eligible for the study. Patients or the legally authorized representative (LAR) will be consented for the study as soon as feasible after the are referred to DeGowin for plasma exchange. The immediate objective of the study is to examine antibody levels (IgG\u002FIgM) and BAFF levels in the blood of these patients over the course of the plasma exchange treatments. Specimens and clinical data will be collected such that other immune factors that may regulate B cell survival, proliferation and antibody secretion can be studied. Another goal of the study is to isolate and cryopreserve PBMCs at different points during the patient's treatment. This would allow the study of immune cells that may mediate these diseases. The study will also follow pathological antibodies over time in these patients so biospecimens can be obtained even after the completion of their course of plasma exchange treatments. The collection of biospecimens and clinical information from these subjects will help us understand the impact of plasma exchange on both normal and pathological immune factors in a variety of patients undergoing these procedures.",[220,221,222,28],"Antibody-mediated Rejection","NMO Spectrum Disorder","TTP",[224,225],"plasma exchange","plasmapheresis","2025-05-15",{"date":228,"type":34},"2025-05-20",{"date":230,"type":34},"2021-07-28",{"date":232,"type":21},"2040-12-31",{"name":234,"class":112},"Charles M Knudson",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":113},"100571022","phase-3-rituximab-induced-remission-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-100571022","NCT06714838","Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy","ReCIX","Inclusion Criteria Group 1 (new\u002Funtreated patients):\n\n* CIDP according to the EAN\u002FPNS criteria (1)\n* Untreated\n* Men and women aged between 18 and 80 years\n* Sufficient CIDP-related disability, as judged by treating physician to warrant IVIg and RTX treatment\n* Capable of giving signed informed consent\n\nInclusion Criteria Group 2 (patients on maintenance treatment):\n\n* CIDP according to the European association of neurology\u002FPeripheral nerve society (EAN\u002FPNS) criteria (1) on maintenance treatment (stable dose\u002Finterval of at least 4 infusions or 3 months), including one of the following categories:\n\n  1. patients with wear-off symptoms before next IVIg infusion captured by at least the minimal clinical important difference (MCID) on at least one outcome measure (see below)\n  2. patients with a failed withdrawal attempt in the last 12 months captured by at least an MCID on at least one outcome measure (see below)\n  3. patients with an increase of IVIg\u002FSCIg dose\u002Finterval in the last 12 months leading to improvement by at least the MCID on at least one outcome measure, see below.\n\n     The most commonly used MCID criteria, namely: 1) one point on the aINCAT disability score (1-10); 2) 4 points on a centile score on I-RODS (disability, 1-100); 3) 2 points on the MRC sum score (muscle strength, 0-60) and 4) 8 kPa on Vigorimeter (grip strength, single or both arms, variable range).\n* Men and women aged between 18 and 80 years\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Paranodopathy with demonstrated (paranodal) antibodies, previously considered part of CIDP spectrum (in these cases rituximab is preferred treatment)\n* Use of drugs associated with a demyelinating neuropathy in the last six months.\n* Known serious adverse events with previous IVIg or RTX treatment. Hypersensitivity to RTX or any component of the formulation. Hypersensitivity to the human immunoglobulins or to any of the excipients. Known selective IgA deficiency patients who developed antibodies to IgA.\n* Positive hepatitis B and C serology suggesting active\u002Funtreated infection (HBsAg, anti-HB core en anti-HBs and HCV antibody (IgG))\n* Ongoing immunosuppressive treatment for other indications.\n* Immunosuppressive treatment other than (already discontinued) corticosteroids in last 6 months.\n* IVIg interval of once every 6 weeks or more than 6 weeks (applies to Group 2 only)\n* Obesity (BMI \\> 35)\n* Known active malignancy (not in remission), currently treated with chemotherapy or immunomodulatory drugs, or with a life expectancy of less than 1 year.\n* History of recurrent\u002Fchronic infections\n* Active, severe infections (such as tuberculosis, sepsis and opportunistic infections)\n* Patients in a severely immunocompromised state Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease\n* Serious co-morbidity as judged by treating physician.\n* Pregnancy or nursing mother; intention to become pregnant during the course of the study; female patients of childbearing potential either not using or not willing to use a medically reliable method of contraception for the entire duration of the study.\n* No written informed consent","80 Years",{"count":244,"type":21},100,[24],"The goal of this clinical trial is to learn if the drug called rituximab causes remission in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The aim is to investigate this in two types of patients, those who are newly diagnosed, and those who are already being treated and are dependent on the current standard therapy: immunoglobulins administered through infusion (IVIg) or through injection (SCIg). The main questions this trial aims to answer are:\n\n* To assess the effectiveness of rituximab\n* Whether it is possible and useful to prescribe patients rituximab who experience a relapse after at least six months after their last rituximab treatment.\n\nParticipants will:\n\n* Receive the drug rituximab twice at the beginning of the trial and one additional time at six months.\n* The newly diagnosed patients will also start another treatment called IVIg, which a nurse will administer every three weeks during the first three to six months.\n* The patients who already being treated, will continue their regular treatment, until this is slowly reduced and stopped, during months three to six.\n* Visit the clinic over the course of two years, during which they will have approximately 10 visits, for checkups and tests.\n* Be asked to fill in questionnaires at each visit, and be asked to have their blood drawn four times.",[28],[249,250,251],"rituximab","remission","IVIg","2024-12-02",{"date":254,"type":34},"2024-12-04",{"date":256,"type":34},"2024-10-16",{"date":258,"type":21},"2028-10",{"name":260,"class":112},"Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)"]